<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Skin and soft tissue infections in neonates: Evaluation and management</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Skin and soft tissue infections in neonates: Evaluation and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Skin and soft tissue infections in neonates: Evaluation and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4185297313"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The evaluation and management of suspected <em>Staphylococcus aureus</em> or streptococcal skin and soft tissue infections (SSTIs) in neonates (≤28 days of age) are discussed here. Clinical features of SSTI; the evaluation and management of staphylococcal and streptococcal SSTIs in children older than 28 days; the epidemiology, prevention, and control of methicillin-resistant <em>S. aureus </em>(MRSA) infections in children; and the treatment of invasive MRSA infections in children are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5790.html" rel="external">"Vesicular, pustular, and bullous lesions in the newborn and infant", section on 'Bacterial infection'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/89273.html" rel="external">"Erythroderma in children", section on 'Infectious diseases'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6027.html" rel="external">"Skin and soft tissue infections in children &gt;28 days: Evaluation and management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6065.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus </i>infections in children: Epidemiology and clinical spectrum"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6025.html" rel="external">"Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) in children: Prevention and control"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections"</a>.)</p><p></p><p class="headingAnchor" id="H3022346934"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Most bacterial skin and soft tissue infections (SSTIs) in neonates are caused by <em>S. aureus</em>. Group B <em>Streptococcus</em> occasionally causes cellulitis. Group A streptococcal SSTIs in neonates are uncommon but may occur. (See  <a class="medical medical_review" href="/d/html/5790.html" rel="external">"Vesicular, pustular, and bullous lesions in the newborn and infant", section on 'Bacterial infection'</a> and  <a class="medical medical_review" href="/d/html/89273.html" rel="external">"Erythroderma in children", section on 'Infectious diseases'</a> and  <a class="medical medical_review" href="/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants", section on 'Other focal infection'</a>.)</p><p class="headingAnchor" id="H82810968"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H4050619578"><span class="h2">History and examination</span><span class="headingEndMark"> — </span>The clinical evaluation of the neonate with suspected bacterial skin and soft tissue infection (SSTI) focuses on identification of systemic infection and clinical manifestations of conditions that require management that differs from that of staphylococcal or streptococcal SSTI in neonates. These conditions often are associated with vesicopustular skin lesions  (<a class="graphic graphic_table graphicRef75417" href="/d/graphic/75417.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/5790.html" rel="external">"Vesicular, pustular, and bullous lesions in the newborn and infant"</a>.)</p><p>Important aspects of the clinical evaluation include:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic signs or symptoms, such as fever (temperature ≥38°C [100.4°F]), hypothermia (temperature &lt;35°C [95°F]), ill-appearance, irritability, and poor feeding</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for sepsis and herpes simplex virus (HSV), which are discussed separately (see  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Maternal risk factors'</a> and  <a class="medical medical_review" href="/d/html/88740.html" rel="external">"Clinical features and diagnosis of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/d/html/8340.html" rel="external">"Genital herpes simplex virus infection and pregnancy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Associated features of congenital HSV, neonatal varicella virus, or congenital syphilis  (<a class="graphic graphic_table graphicRef76743" href="/d/graphic/76743.html" rel="external">table 2</a>) (see  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Neonatal HSV'</a> and  <a class="medical medical_review" href="/d/html/4969.html" rel="external">"Varicella-zoster infection in the newborn", section on 'Neonatal varicella'</a> and  <a class="medical medical_review" href="/d/html/14428.html" rel="external">"Congenital syphilis: Clinical manifestations, evaluation, and diagnosis", section on 'Early congenital syphilis'</a>)</p><p></p><p class="headingAnchor" id="H2484336351"><span class="h2">Laboratory evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gram stain, culture, and susceptibility testing of purulent material</strong> – We obtain specimens for Gram stain, culture, and susceptibility testing from neonates with purulent/fluctuant skin lesions (ie, abscesses) if purulent material can be obtained [<a href="#rid1">1-3</a>].</p><p></p><p class="bulletIndent1">Gram stain identification of gram-positive cocci may help to guide empiric therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gram stain identification of gram-positive cocci in clusters provides early indication of staphylococcal infection. If <em>S. aureus</em> is isolated in bacterial culture, susceptibility testing is necessary to distinguish methicillin-resistant <em>S. aureus</em> from methicillin-susceptible <em>S. aureus</em> [<a href="#rid4">4</a>]. In some laboratories, methicillin resistance may be detected rapidly using commercially available molecular tests for the mecA gene that leads to methicillin resistance. (See  <a class="medical medical_review" href="/d/html/3166.html" rel="external">"Rapid detection of methicillin-resistant Staphylococcus aureus"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gram stain identification of gram-positive cocci in chains provides early identification of streptococcal infection. Culture is necessary to distinguish between group A and group B <em>Streptococcus</em>. The empiric treatment of neonatal group B streptococcal infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants", section on 'Antimicrobial therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other studies</strong> – Our approach to obtaining other laboratory studies and cultures in neonates with suspected bacterial SSTI depends upon the type of infection and associated systemic findings. Systemic findings include fever (temperature ≥38°C [100.4°F]), hypothermia (temperature &lt;35°C [95°F]), ill-appearance, irritability, and poor feeding.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neonates with mastitis</strong> – The evaluation of neonates with mastitis is discussed separately. (See  <a class="medical medical_review" href="/d/html/5974.html" rel="external">"Mastitis and breast abscess in infants younger than two months", section on 'Additional evaluation'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Term neonates (≥37 weeks gestation) with localized pustulosis and no systemic findings</strong> – Localized pustulosis  (<a class="graphic graphic_picture graphicRef107272" href="/d/graphic/107272.html" rel="external">picture 1</a>) usually is caused by <em>S. aureus</em>. We generally do not obtain blood cultures or other microbiologic studies unless it is necessary to distinguish staphylococcal pustulosis from other causes of pustular lesions  (<a class="graphic graphic_table graphicRef75417" href="/d/graphic/75417.html" rel="external">table 1</a>) [<a href="#rid5">5</a>]. In otherwise asymptomatic neonates with pustulosis, the Gram stain is helpful in distinguishing pustulosis from other conditions. If HSV remains a possibility, the infant should undergo full evaluation for HSV. (See  <a class="medical medical_review" href="/d/html/6037.html" rel="external">"Neonatal herpes simplex virus infection: Clinical features and diagnosis", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preterm (&lt;37 weeks gestation), low birth weight neonates with localized pustulosis (with or without systemic findings)</strong> – We usually obtain blood cultures.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Term or preterm neonates with multiple sites of pustulosis, other types of SSTI (eg, cellulitis, abscess, mastitis), or systemic findings</strong> – We obtain blood and urine cultures in all such patients and cerebrospinal fluid (CSF) cultures as clinically indicated (eg, fever/hypothermia, ill-appearing) [<a href="#rid2">2</a>]. Indications for CSF cultures in neonates are discussed separately:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Preterm neonates (&lt;34 weeks gestation) (see  <a class="medical medical_review" href="/d/html/88740.html" rel="external">"Clinical features and diagnosis of bacterial sepsis in preterm infants &lt;34 weeks gestation", section on 'Other cultures'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Term (&gt;37 weeks gestation) and late preterm (34 to 36 weeks gestation) neonates &lt;7 days (see  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Early-onset presentation'</a>)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Term and late preterm neonates ≥7 days of age (see  <a class="medical medical_review" href="/d/html/134347.html" rel="external">"The febrile neonate (28 days of age or younger): Outpatient evaluation and initial management", section on 'Focal infection'</a> and  <a class="medical medical_review" href="/d/html/6072.html" rel="external">"The febrile infant (29 to 90 days of age): Outpatient evaluation", section on 'Focal infection'</a>)</p><p></p><p class="bulletIndent2">Significant CSF pleocytosis with sterile CSF culture may be seen in association with community-associated <em>S. aureus</em> infection in neonates [<a href="#rid2">2,5</a>]. The pathogenesis of the pleocytosis is unclear.</p><p></p><p class="headingAnchor" id="H1383900093"><span class="h1">MANAGEMENT APPROACH</span></p><p class="headingAnchor" id="H3544538838"><span class="h2">Localized pustulosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Term neonates without systemic findings </strong>– We suggest that localized pustulosis  (<a class="graphic graphic_picture graphicRef107272" href="/d/graphic/107272.html" rel="external">picture 1</a>) in term neonates (≥37 weeks gestation) without systemic findings (fever, hypothermia, ill-appearance, irritability, poor feeding) be treated with topical antibiotic therapy (eg, <a class="drug drug_pediatric" data-topicid="12622" href="/d/drug information/12622.html" rel="external">mupirocin</a> three times daily for 5 to 10 days) in the outpatient setting  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>) [<a href="#rid1">1,2</a>]; close follow-up of such patients is imperative [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Term neonates with systemic findings</strong> – We use parenteral rather than topical therapy for full-term neonates with localized pustulosis and fever or other signs or symptoms of systemic infection  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>). (See <a class="local">'Choice of initial therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preterm (&lt;37 weeks gestation) low birth weight neonates</strong> – We recommend that local pustulosis in preterm (&lt;37 weeks gestation) low birth weight infants be treated parenterally at least until bacteremia is excluded  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>) [<a href="#rid1">1</a>]. If blood cultures were not obtained, a five- to seven-day course of parenteral therapy is reasonable – provided that the infant continues to be clinically well and the pustulosis resolved completely. (See <a class="local">'Choice of initial therapy'</a> below and <a class="local">'Duration of therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H2566049618"><span class="h2">SSTI more severe than localized pustulosis</span><span class="headingEndMark"> — </span>We hospitalize neonates with skin and soft tissue infection (SSTI) more severe than localized pustulosis (eg, multiple sites of pustulosis, mastitis and other sites of cellulitis, abscess) for close monitoring and parenteral antimicrobial therapy  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>) [<a href="#rid2">2</a>]. In addition to provision of parenteral antimicrobial therapy, we recommend drainage of purulent or fluctuant lesions (eg, cutaneous abscess). (See <a class="local">'Choice of initial therapy'</a> below.)</p><p>Neonates with SSTI other than localized pustulosis are at increased risk for sepsis and invasive infection (given the immaturity of their immune system). (See  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates"</a>.)</p><p>Clinical features and clinical decision rules cannot accurately predict serious bacterial infection in young infants. Neonates with SSTI other than localized pustulosis typically have undergone evaluation for one or more concomitant serious bacterial infection (eg, bacteremia, urinary tract infection, meningitis, osteoarticular infection) and are treated with parenteral antimicrobial therapy until 48-hour culture results are available.</p><p class="headingAnchor" id="H2164651994"><span class="h1">ANTIMICROBIAL THERAPY</span><span class="headingEndMark"> — </span>The safety and efficacy of topical, oral, and parenteral antimicrobial therapy for staphylococcal and streptococcal skin and soft tissue infection (SSTI) in neonates have not been well evaluated in clinical studies. We generally provide empiric coverage for <em>S. aureus</em> and add coverage for other pathogens as clinically indicated  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>).</p><p>Our approach to antimicrobial therapy is consistent with that provided by the Infectious Diseases Society of America [<a href="#rid1">1</a>], which is based upon observations from a review of 126 cases treated between 2001 and 2006 at the author's institution [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H986900721"><span class="h2">Choice of initial therapy</span><span class="headingEndMark"> — </span>The empiric parenteral antibiotic regimen for suspected staphylococcal or streptococcal SSTI in neonates should be based upon the type of infection and local susceptibility pattern of community-associated <em>S. aureus</em> isolates. When the etiologic agent and susceptibility are known, antimicrobial therapy can be narrowed as indicated.</p><p class="headingAnchor" id="H667914192"><span class="h3">SSTI without systemic findings</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SSTI other than cellulitis </strong>– For neonates with SSTI other than cellulitis and no systemic findings (eg, fever, hypothermia, ill-appearance, irritability, poor feeding), we provide initial empiric coverage for methicillin-resistant <em>S. aureus</em> (MRSA) with <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> or <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a>, given the high prevalence of MRSA in our community  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef107674" href="/d/graphic/107674.html" rel="external">table 3</a>) [<a href="#rid1">1,2</a>]. For those infants in whom gram-negative pathogens are not a concern, monotherapy with <a class="drug drug_pediatric" data-topicid="12555" href="/d/drug information/12555.html" rel="external">linezolid</a> or <a class="drug drug_pediatric" data-topicid="109476" href="/d/drug information/109476.html" rel="external">ceftaroline</a> is an option in selected circumstances (eg, infection due to MRSA resistant to clindamycin in an infant with underlying renal dysfunction). Ceftaroline is available for infants born at ≥34 weeks' gestation and ≥12 days of age [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">In communities where MRSA is less prevalent (eg, ≤15 percent of <em>S. aureus</em> isolates), initial empiric coverage for methicillin-susceptible <em>S. aureus</em> (MSSA) is an alternative  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>); other experts may have a different threshold of MRSA prevalence for MSSA coverage. Agents active against MSSA include <a class="drug drug_pediatric" data-topicid="12626" href="/d/drug information/12626.html" rel="external">nafcillin</a>, <a class="drug drug_pediatric" data-topicid="12663" href="/d/drug information/12663.html" rel="external">oxacillin</a>, or <a class="drug drug_pediatric" data-topicid="13124" href="/d/drug information/13124.html" rel="external">cefazolin</a>; <a class="drug drug_pediatric" data-topicid="12708" href="/d/drug information/12708.html" rel="external">piperacillin-tazobactam</a> is an alternative if it is necessary for another indication (eg, <em>Pseudomonas</em>)  (<a class="graphic graphic_table graphicRef107674" href="/d/graphic/107674.html" rel="external">table 3</a>). Parenteral coverage should be broadened to include MRSA, group B <em>Streptococcus</em> (GBS), and enteric gram-negative pathogens if the infant develops systemic findings and to include MRSA, GBS, and other beta-hemolytic streptococci if the infant develops cellulitis. (See <a class="local">'SSTI with systemic findings'</a> below.)</p><p></p><p class="bulletIndent1">Studies comparing antistaphylococcal regimens in neonates with SSTI are lacking. The antibiotics suggested above are equally reasonable based upon in vitro data and clinical observations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cellulitis</strong> – For neonates with cellulitis and no systemic findings, we provide coverage for GBS<em> </em>and other beta-hemolytic streptococci in addition to MRSA  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>). Empiric parenteral therapy options include <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> plus either an extended spectrum cephalosporin (eg, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a> [if available], <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a>, <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a>) or <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>  (<a class="graphic graphic_table graphicRef107674" href="/d/graphic/107674.html" rel="external">table 3</a>).</p><p></p><p class="headingAnchor" id="H3683681263"><span class="h3">SSTI with systemic findings</span><span class="headingEndMark"> — </span>For neonates with suspected staphylococcal or streptococcal infection who have systemic findings (eg, fever, hypothermia, ill-appearance, irritability, poor feeding) it is usually necessary to add coverage for other neonatal pathogens (ie, <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a> [if available], <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a>, <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a>, or <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a> for enteric gram-negative pathogens)  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>). Ceftriaxone should be avoided in neonates with hyperbilirubinemia and in neonates receiving calcium-containing intravenous fluids. (See  <a class="medical medical_review" href="/d/html/5043.html" rel="external">"Clinical features, evaluation, and diagnosis of sepsis in term and late preterm neonates", section on 'Etiologic agents'</a>.)</p><p>The combination of <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a> plus one of these agents provides adequate empiric therapy for possible GBS cellulitis but is not appropriate for sepsis or meningitis  (<a class="graphic graphic_table graphicRef107674" href="/d/graphic/107674.html" rel="external">table 3</a>). Appropriate antimicrobial regimens for neonatal sepsis and meningitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/5046.html" rel="external">"Management and outcome of sepsis in term and late preterm neonates", section on 'Initial empiric therapy'</a> and  <a class="medical medical_review" href="/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants", section on 'Antimicrobial therapy'</a>.)</p><p class="headingAnchor" id="H2391063259"><span class="h2">Duration of therapy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SSTI confined to the skin and soft tissues</strong> — The total duration of therapy for staphylococcal or streptococcal SSTI confined to the skin and soft tissues in neonates depends upon clinical response; a total of 7 to 14 days is usually adequate if there are no complications [<a href="#rid2">2</a>]. (See <a class="local">'Response to therapy'</a> below.)</p><p></p><p class="bulletIndent1">For neonates with SSTI confined to the skin and soft tissues, we continue parenteral therapy at least until all of the following criteria are met (see <a class="local">'Response to therapy'</a> below):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Resolution of systemic symptoms and fever</p><p class="bulletIndent2"><span class="glyph">•</span>Improvement in other clinical findings</p><p class="bulletIndent2"><span class="glyph">•</span>Antibiotic susceptibility results are available if a pathogen is isolated</p><p class="bulletIndent2"><span class="glyph">•</span>Systemic bacterial cultures (eg, blood, urine, cerebrospinal fluid) isolate no pathogens during at least 48 hours of incubation</p><p></p><p class="bulletIndent1">Although we obtain blood cultures in preterm, low birth weight neonates with localized pustulosis, if blood cultures were not obtained, a five- to seven-day course of parenteral therapy is reasonable, provided that the infant continues to be clinically well and the pustulosis is completely resolved.</p><p></p><p class="bulletIndent1">Results of antibiotic susceptibility testing should be used to make decisions about which oral antibiotic to use for continuation of systemic therapy. Appropriate oral agents for neonates with SSTI include <a class="drug drug_pediatric" data-topicid="13138" href="/d/drug information/13138.html" rel="external">cephalexin</a> and <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a>, depending upon the susceptibilities of the isolate  (<a class="graphic graphic_table graphicRef107674" href="/d/graphic/107674.html" rel="external">table 3</a>) [<a href="#rid7">7,8</a>]. Oral <a class="drug drug_pediatric" data-topicid="12555" href="/d/drug information/12555.html" rel="external">linezolid</a> may be used when the isolate is resistant to other agents, but, given its high cost, consultation with an expert in infectious diseases may be warranted to make sure that it is the only oral option [<a href="#rid2">2</a>]. If a pathogen is not isolated, we continue coverage with an oral agent with activity against both MRSA and MSSA (eg, clindamycin). <a class="drug drug_pediatric" data-topicid="12816" href="/d/drug information/12816.html" rel="external">Trimethoprim-sulfamethoxazole</a> should not be used in neonates because it may displace bilirubin, increasing the risk for bilirubin toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive infection</strong> — The duration of antimicrobial therapy for neonates with staphylococcal or GBS infections that have extended beyond the skin and soft tissues is discussed separately. (See  <a class="medical medical_review" href="/d/html/6057.html" rel="external">"<i>Staphylococcus aureus </i>in children: Overview of treatment of invasive infections", section on 'Treatment of neonates'</a> and  <a class="medical medical_review" href="/d/html/5961.html" rel="external">"Group B streptococcal infection in neonates and young infants", section on 'Antimicrobial therapy'</a>.)</p><p></p><p class="headingAnchor" id="H303049436"><span class="h1">RESPONSE TO THERAPY</span></p><p class="headingAnchor" id="H2676982012"><span class="h2">Monitoring response</span><span class="headingEndMark"> — </span>Response to therapy is indicated by clinical improvement after 48 hours. In neonates who are admitted to the hospital for antimicrobial therapy, we monitor the skin and soft tissue infection (SSTI) for improvement or progression, the patient's vital signs, and culture and susceptibility results (if obtained).</p><p>Neonates who are treated for staphylococcal or streptococcal SSTI in the outpatient setting should be instructed to seek medical care promptly if they develop systemic symptoms (eg, fever, hypothermia, irritability, ill-appearance, poor feeding) or if local symptoms worsen [<a href="#rid9">9</a>]. They should be seen for follow-up within 48 hours. Follow-up is essential to ensure clinical improvement and determine the need for drainage, additional drainage (if drained initially), or change in antimicrobial therapy.</p><p class="headingAnchor" id="H1691103163"><span class="h2">Failure to respond</span><span class="headingEndMark"> — </span>Initiation of systemic therapy (for neonates initially treated with topical antibiotics) or change in antimicrobial therapy (guided by culture and susceptibility results, if available) is indicated for neonates who worsen at any time during treatment and may be warranted for patients who remain stable but whose skin lesions have not improved after 48 hours of observation or antimicrobial therapy.</p><p>Possible explanations for failure to respond in neonates receiving an agent to which their isolate is susceptible include inadequate drainage (if drainage was performed), abscess recurrence, or development of a new abscess. Ultrasonography may identify residual, recurrent, or new abscesses that require drainage.</p><p>In a retrospective study of 202 neonates treated with antibiotics for an uncomplicated SSTI, perirectal site of the infection was a risk factor for antibiotic treatment failure (17 percent with perirectal infections versus 5 percent with other types of infection [odds ratio 4.1, 95% CI 1.5-11.3]) [<a href="#rid10">10</a>].</p><p>If cultures remain negative and ultrasonography does not identify lesions that require drainage, a change in empiric therapy may be indicated (eg, to include coverage for methicillin-resistant <em>S. aureus </em>[MRSA] if MRSA was not initially included). In such cases, consultation with an expert in infectious diseases is suggested.</p><p class="headingAnchor" id="H716327276"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110086.html" rel="external">"Society guideline links: Skin and soft tissue infections"</a>.)</p><p class="headingAnchor" id="H1905713806"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15481.html" rel="external">"Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4025.html" rel="external">"Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H943113269"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical evaluation of the neonate with suspected <em>Staphylococcus aureus</em> or streptococcal skin and soft tissue infection (SSTI) focuses on identification of systemic infection and clinical manifestations of conditions that require management that differs from the management of staphylococcal or streptococcal SSTI in neonates. These conditions often are associated with vesicopustular skin lesions  (<a class="graphic graphic_table graphicRef75417" href="/d/graphic/75417.html" rel="external">table 1</a>). (See <a class="local">'History and examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We obtain specimens for Gram stain, culture, and susceptibility testing from neonates with purulent/fluctuant skin lesions (abscess) if purulent material can be obtained. Our approach to obtaining other laboratory studies and cultures in neonates with suspected bacterial SSTI depends upon the type of infection and associated clinical features. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For full term neonates with localized pustulosis  (<a class="graphic graphic_picture graphicRef107272" href="/d/graphic/107272.html" rel="external">picture 1</a>) and no systemic findings (eg, temperature ≥38°C [100.4°F] or &lt;35°C [95°F], ill-appearance, irritability, poor feeding), we suggest topical rather than systemic therapy  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We generally use <a class="drug drug_pediatric" data-topicid="12622" href="/d/drug information/12622.html" rel="external">mupirocin</a> three times daily for 5 to 10 days. Close outpatient follow-up is essential. (See <a class="local">'Localized pustulosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We hospitalize preterm low birth weight neonates with localized pustulosis for parenteral therapy. We also hospitalize neonates with SSTI more severe than localized pustulosis (eg, pustulosis in multiple sites, cellulitis, abscess, mastitis) and neonates who undergo evaluation for serious bacterial infection (eg, bacteremia, urinary tract infection, meningitis, arthritis, osteomyelitis). (See <a class="local">'Localized pustulosis'</a> above and <a class="local">'SSTI more severe than localized pustulosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The empiric parenteral antibiotic regimen for suspected staphylococcal or streptococcal SSTI in neonates should be based upon the type of infection and local susceptibility pattern of community-associated <em>S. aureus</em> isolates  (<a class="graphic graphic_algorithm graphicRef113285" href="/d/graphic/113285.html" rel="external">algorithm 1</a>). In areas with an increased prevalence of methicillin-resistant <em>S. aureus</em>, <a class="drug drug_pediatric" data-topicid="12874" href="/d/drug information/12874.html" rel="external">vancomycin</a>, <a class="drug drug_pediatric" data-topicid="13167" href="/d/drug information/13167.html" rel="external">clindamycin</a>, and <a class="drug drug_pediatric" data-topicid="12555" href="/d/drug information/12555.html" rel="external">linezolid</a> or <a class="drug drug_pediatric" data-topicid="109476" href="/d/drug information/109476.html" rel="external">ceftaroline</a> are appropriate alternatives for infection limited to the skin and soft tissues; <a class="drug drug_pediatric" data-topicid="13332" href="/d/drug information/13332.html" rel="external">gentamicin</a>, <a class="drug drug_pediatric" data-topicid="13129" href="/d/drug information/13129.html" rel="external">cefotaxime</a> (if available), <a class="drug drug_pediatric" data-topicid="13134" href="/d/drug information/13134.html" rel="external">ceftazidime</a>, <a class="drug drug_pediatric" data-topicid="13126" href="/d/drug information/13126.html" rel="external">cefepime</a>, or <a class="drug drug_pediatric" data-topicid="13136" href="/d/drug information/13136.html" rel="external">ceftriaxone</a> may be added to broaden coverage  (<a class="graphic graphic_table graphicRef107674" href="/d/graphic/107674.html" rel="external">table 3</a>). When the etiologic agent and susceptibility are known, antimicrobial therapy can be narrowed as indicated. (See <a class="local">'Choice of initial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The duration of therapy for staphylococcal or streptococcal SSTI confined to the skin and soft tissues in neonates depends upon clinical response; a total of 7 to 14 days is usually adequate if there are no complications. (See <a class="local">'Duration of therapy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.</a></li><li class="breakAll">American Academy of Pediatrics. Staphylococcus aureus. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.678.</li><li><a class="nounderline abstract_t">Miller LG, Perdreau-Remington F, Bayer AS, et al. Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation. Clin Infect Dis 2007; 44:471.</a></li><li><a class="nounderline abstract_t">Day CT, Kaplan SL, Mason EO, Hulten KG. Community-associated Staphylococcus aureus infections in otherwise healthy infants less than 60 days old. Pediatr Infect Dis J 2014; 33:98.</a></li><li class="breakAll">Teflaro (ceftaroline fosamil) for injection. United States Prescribing Information. Revised September 2019. US Food &amp; Drug Administration. (Available online http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (Accessed on October 22, 2019).</li><li><a class="nounderline abstract_t">Autret E, Laugier J, Marimbu J, et al. [Comparison of plasma levels of amoxicillin administered by oral and intravenous routes in neonatal bacterial colonization]. Arch Fr Pediatr 1988; 45:679.</a></li><li><a class="nounderline abstract_t">Boothman R, Kerr MM, Marshall MJ, Burland WL. Absorption and excretion of cephalexin by the newborn infant. Arch Dis Child 1973; 48:147.</a></li><li><a class="nounderline abstract_t">Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J 2008; 27:1.</a></li><li><a class="nounderline abstract_t">Patel P, Foster CE, Stimes G, et al. Risk Factors for Treatment Failure in Neonates With Skin and Soft Tissue Infection: A Retrospective Cohort Study. Clin Pediatr (Phila) 2023; :99228231189132.</a></li></ol></div><div id="topicVersionRevision">Topic 106447 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17974729" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17974729" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17243048" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical and epidemiologic characteristics cannot distinguish community-associated methicillin-resistant Staphylococcus aureus infection from methicillin-susceptible S. aureus infection: a prospective investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23934207" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Community-associated Staphylococcus aureus infections in otherwise healthy infants less than 60 days old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23934207" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Community-associated Staphylococcus aureus infections in otherwise healthy infants less than 60 days old.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3233058" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : [Comparison of plasma levels of amoxicillin administered by oral and intravenous routes in neonatal bacterial colonization].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4690512" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Absorption and excretion of cephalexin by the newborn infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162929" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37491834" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk Factors for Treatment Failure in Neonates With Skin and Soft Tissue Infection: A Retrospective Cohort Study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
